Biocept, Inc., a leading commercial provider of clinically actionable liquid biopsy tests designed to improve the outcomes of cancer patients, announces that Columbia University Medical Center will conduct a study to evaluate the clinical utility of the Company's Target Selectorâ„¢ platform to diagnose leptomeningeal metastases (LM) in patients with breast cancer.
More...